FORA Capital LLC Invests $488,000 in ICU Medical, Inc. (NASDAQ:ICUI)

FORA Capital LLC purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,148 shares of the medical instruments supplier’s stock, valued at approximately $488,000.

Other hedge funds have also added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after buying an additional 8,010 shares during the last quarter. Principal Financial Group Inc. lifted its position in ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after acquiring an additional 25,031 shares during the last quarter. Vanguard Group Inc. grew its position in shares of ICU Medical by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after purchasing an additional 17,805 shares during the last quarter. Jennison Associates LLC bought a new position in shares of ICU Medical during the fourth quarter worth approximately $556,000. Finally, Franklin Resources Inc. lifted its holdings in ICU Medical by 99.3% during the 3rd quarter. Franklin Resources Inc. now owns 11,708 shares of the medical instruments supplier’s stock worth $2,111,000 after purchasing an additional 5,834 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

ICUI has been the subject of a number of research reports. KeyCorp dropped their target price on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Raymond James decreased their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average target price of $192.67.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $138.30 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The company has a market cap of $3.40 billion, a PE ratio of -30.26 and a beta of 0.87. The company has a 50 day moving average of $140.67 and a 200-day moving average of $155.29. ICU Medical, Inc. has a 1-year low of $100.91 and a 1-year high of $196.26.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.49. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The firm had revenue of $599.49 million during the quarter, compared to analysts’ expectations of $574.15 million. During the same period in the prior year, the company earned $0.96 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, equities research analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.